264 related articles for article (PubMed ID: 33746213)
21. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of
Ma J; Li L; Liao T; Gong W; Zhang C
Front Oncol; 2022; 12():796657. PubMed ID: 35186737
[TBL] [Abstract][Full Text] [Related]
23. Radioligand Therapy With
Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
[No Abstract] [Full Text] [Related]
24. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
25. Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Privé BM; Slootbeek PHJ; Laarhuis BI; Naga SP; van der Doelen MJ; van Kalmthout LWM; de Keizer B; Ezziddin S; Kratochwil C; Morgenstern A; Bruchertseifer F; Ligtenberg MJL; Witjes JA; van Oort IM; Gotthardt M; Heskamp S; Janssen MJR; Gerritsen WR; Nagarajah J; Mehra N
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):71-78. PubMed ID: 34253846
[TBL] [Abstract][Full Text] [Related]
26.
Khreish F; Ebert N; Ries M; Maus S; Rosar F; Bohnenberger H; Stemler T; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):721-728. PubMed ID: 31758224
[TBL] [Abstract][Full Text] [Related]
27. Update on radioligand therapy with
Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M
Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748
[TBL] [Abstract][Full Text] [Related]
28. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
29. 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.
AlSadi R; Bouhali O; Dewji S; Djekidel M
Oncologist; 2022 Dec; 27(12):e957-e966. PubMed ID: 36288537
[TBL] [Abstract][Full Text] [Related]
30. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing
Rathke H; Kratochwil C; Hohenberger R; Giesel FL; Bruchertseifer F; Flechsig P; Morgenstern A; Hein M; Plinkert P; Haberkorn U; Bulut OC
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):139-147. PubMed ID: 30151743
[TBL] [Abstract][Full Text] [Related]
31. Response Assessment and Prediction of Progression-Free Survival by
Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
[No Abstract] [Full Text] [Related]
33. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
34. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
35. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
36. Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy.
Satapathy S; Sharma A; Sood A; Maheshwari P; Gill HJS
Clin Nucl Med; 2022 Jun; 47(6):e466-e467. PubMed ID: 35353746
[TBL] [Abstract][Full Text] [Related]
37. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
38. PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
Banda A; Privé BM; Allach Y; Uijen MJM; Peters SMB; Loeff CC; Gotthardt M; Muselaers CHJ; Witjes JA; van Oort IM; Sedelaar JPM; Westdorp H; Mehra N; Khreish F; Ezziddin S; Sabet A; Kreissl MC; Winkens T; Seifert P; Janssen MJR; van Gemert WAM; Nagarajah J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612293
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of [
Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003
[TBL] [Abstract][Full Text] [Related]
40. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]